拜耳药物asundexian在三期试验中降低中风风险，重燃FXIa类药物希望

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.